Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | CPT2 | P23786 | 2/20 | 0.50 |
| ▸ | CPT1A | P50416 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308004 | 1.00 | CYP19A1 (0.50) | CYP19A1CPT2CPT1ACYP2A6CPT1B | |
| SCHEMBL2311565 | 0.84 | CPT2 (0.47) | CYP19A1CPT2CPT1ACYP2A6CPT1B | |
| SCHEMBL2311560 | 0.84 | CPT2 (0.47) | CYP19A1CPT2CPT1ACYP2A6CPT1B | |
| SCHEMBL2303917 | 0.79 | CPT1A (0.49) | CPT2CPT1ACYP2A6CPT1BIRAK4 | |
| SCHEMBL2303909 | 0.79 | CPT1A (0.49) | CPT2CPT1ACYP2A6CPT1BIRAK4 | |
| SCHEMBL2310395 | 0.76 | KDM4E (0.46) | CYP19A1CPT1ACYP2A6 | |
| SCHEMBL2310391 | 0.76 | KDM4E (0.46) | CYP19A1CPT1ACYP2A6 | |
| SCHEMBL2311020 | 0.76 | CPT1A (0.52) | CPT2CPT1A | |
| SCHEMBL2311015 | 0.76 | CPT1A (0.52) | CPT2CPT1A | |
| SCHEMBL2306060 | 0.76 | SMN1; SMN2 (0.44) | CYP19A1CPT1ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039487-B2 | Piperidine-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2155738-B1 | PIPERIDINE-AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2155738-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
| WO-2008145596-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | CYP19A1 383/4885CPT2 3/4885CPT1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.